Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone-receptor Positive Breast Cancer
Interventions: DRUG: Pyrotinib|DRUG: Epirubicin|DRUG: Doxorubicin Hydrochloride Liposome Injection|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Nab paclitaxel|DRUG: Placebo
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.